Navigation Links
Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinson's Disease
Date:1/22/2009

Study Recruiting Adult Parkinson's Patients with Behavioral Changes

KING OF PRUSSIA, Pa., Jan. 22 /PRNewswire/ -- Parkinson's disease affects 6.3 million people worldwide. While the disease is recognized for its profound effects on movement such as tremors, less known is that 1 in 3 Parkinson's disease patients will develop changes that include hallucinations, illusions and delusions.

ACADIA Pharmaceuticals, a biopharmaceutical company headquartered in San Diego is currently conducting a study aimed at improving the quality of life for people with Parkinson's disease and its behavioral complications. The company recently received an award from the Michael J. Fox Foundation for its continuing work in Parkinson's research.

ACADIA Pharmaceuticals is now evaluating an investigational medication that researchers hope will help treat the cognitive and behavioral changes caused by Parkinson's. As Parkinson's disease progresses, up to 40 percent of patients can experience what is called 'Parkinson's Psychosis.' A condition in which patients experience changes in thought, behavior and judgment that can have devastating effects. In more advanced stages these symptoms include hallucinations, illusions and delusions where patients see things that aren't really there, believe things that are untrue, create false ideas and falsely accuse those closest to them.

"While the physical manifestations of Parkinson's disease are difficult to deal with, the changes in thought, behavior and judgment strain the bonds between patients and their caregivers and families," said expert Dr. Bernard Ravina, Director of the Movement and Inherited Neurological Disorders Unit at the University of Rochester in New York.

An online survey conducted by Med
'/>"/>

SOURCE MediciGlobal
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
2. Life Sciences Organizations Choose Oracle to Accelerate and Simplify Clinical Trial Data Collection
3. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
4. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
5. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
8. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced today that ... an update on the progress of Sangamo,s ZFP Therapeutic ® ... strategy at 1:30pm ET on Monday, June 1, 2015, at ... held in New York, NY . ... accessed via a link on the Sangamo BioSciences website in ...
(Date:5/26/2015)... -- Alere Inc. (NYSE: ALR ) (the "Company") announced today ... its Quarterly Report on Form 10-Q for the three months ... a notice from the New York Stock Exchange (the "NYSE") ... continued listing requirements under the timely filing criteria established in ... The reason for the delay relates to Company,s need ...
(Date:5/26/2015)... Global Stem Cells Group and Stem ... first cellular and regenerative medicine symposium in Barcelona Spain ... stem cell training class Oct. 10. The event will ... of Therapeutic Confrontations (CONFTERA) in Barcelona. , In ... medicine and recent advances in cellular therapies, Global Stem ...
(Date:5/26/2015)... May 26, 2015   PDI , a ... announced that Oakwood Healthcare in Dearborn, ... winning entry in Delivering the Difference ... display excellence in building collaborative relationships between infection ... healthcare facilities.  Oakwood Healthcare,s infection ...
Breaking Biology Technology:Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3
... May 3, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: ... a leading China-based biotechnology company focused on researching, ... that it will release its first quarter 2011 ...  closes on Wednesday, May 11, 2011 at 8:00pm ...
... this year,s American Academy of AntiAging (A4M) conference, Glycation and ... in premature aging and disease. AGEs are dangerous substances that ... attaches to a protein or lipid without the presence of ... cause accelerated damage to the tissues and cells. ...
... Pharmaceuticals, Inc. (AMEX: AEN ), a developer ... announced today that after scientific review, the ongoing clinical ... multiple sclerosis (MS) has received an additional $1,594,553 in ... of Neurological Disorders and Stroke (NIH/NINDS). The clinical trial ...
Cached Biology Technology:3SBio Inc. Schedules Unaudited First Quarter 2011 Results 2At This Year's American Academy of AntiAging (A4M) Conference, Glycation and AGEs (Advanced Glycation End Products) Were Named the Leading Factors in Premature Aging and Disease 2Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 2Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 3Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 4
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... Access to Research Careers) Program has announced the travel ... of Chicanos and Native Americans in Science (SACNAS) annual ... These awards are meant to promote the entry of ... mainstream of the basic science community and to encourage ...
... Fox Foundation for Parkinson,s Research and Shake It Up ... Sydney,s Garvan Institute of Medical Research to look at ... Long non-coding RNAs are complex molecules, produced from ... in the body. Unlike conventional genes, they do not ...
... have increasingly relied on the wild and weedy relatives of ... and other traits. But just like all wild plant species, ... decline and extinction due to habitat loss, pollution, and climate ... describe the latest efforts to identify and protect the wild ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Protecting the weedy and wild kin of globally important crops 2
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
For demonstration of Helicobacter pylori...
... with SR-101 Labeled Substrates (red fluorescence; ... measure serine protease activation • No ... FLISP Kits utilize cell-permeable, fluorescently labeled ... measure chymotrypsin-like activity in whole living ...
... the mitochondrial transmembrane potential is ... events that occur following induction ... Detection Kit utilizes a lipophilic ... a mitochondrial activity marker. MitoLight ...
Biology Products: